Researchers and medical experts expressed concerns about the safety of Pfizer's Celebrex and Bextra, linking them to potential heart problems similar to those seen with Vioxx.
The FDA faced criticism for not acting sooner on Vioxx warnings, leading to questions about drug safety monitoring.
Merck's decision to withdraw Vioxx highlighted flaws in the drug approval process and raised calls for more rigorous testing.
Pfizer is now investigating Bextra's potential heart risks, following in the footsteps of Vioxx's withdrawal due to cardiovascular concerns.
Patients are advised to consult their doctors for alternative pain relief options amidst ongoing safety debates in the pharmaceutical industry.
